CSL Plasma competitors

Nasrat Hakim is a Founder at Mikah Pharma LLC and is based in Greater New York City Area. He has worked as Vice President, Quality, Compliance and Technical Services at ALLERGAN; Board Member at ELITE PHARMACEUTICALS INC /NV/; and President & CEO at ELITE PHARMACEUTICALS INC /NV/. Nasrat works or has worked at Watson Inc. and works or has worked as VP:Technical Svcs at Actavis, Exec Dir:Quality Unit at Theratech Inc., and VP:Quality & Regulatory at Alpharma. He attended California State University-Sacramento between 1989 and 1989, California State University Long Beach, and St. Thomas University School of Law between 2004 and 2006.

Execution-oriented Senior Business Executive who has held multiple Company Officer, President and General Manager positions. Extensive hands-on experience of both Strategy and Operational management in the Biotechnology / Pharmaceutical / Life Sciences / Medical Device industry. Deep expertise in managing the full product life cycle, ranging from development and launch to mid-life and patent expiry. Leadership in growth and turn-around situations, all requiring extensive change management in culturally diverse organizations. Adept at cross-functional leadership within complex matrix organizations with in-depth understanding of the capabilities of all key functions. Proven financial management ability. Skilled at developing and sustaining Alliances, Partnerships and Joint Ventures. A genuine globalist, having worked and lived in eight different countries as well as having had responsibility for business operations in more than 50 other countries. Selected Achievements: • Provided the leadership needed to gain regulatory approval by both FDA and NRC of a novel radiochemical separation system and radiochemical manufacturing operation. Subsequently executed a product enhancement roadmap to provide the features required for product success and scale-up production to meet market needs. • Restructured a $500M International business to optimize profitability while “spinning-out” from parent company • Transformed a $300M business in Brazil to drive growth of key new products • Negotiated and executed a Partnership for Productive Development with Brazilian MoH for an HIV product • Led business and product divestitures in multiple markets, worth in excess of $1B • Work-stream lead for a team which developed and executed a highly successful turnaround strategy for a Major BioPharma Company • Implemented an efficient and innovative new sales structure for a U.S. Business Former Submarine Navigation and Operations Officer - British Royal Navy